Patient-reported outcomes (PROs) in patients (pts) with pancreatic neuroendocrine tumors (NET) receiving sunitinib (SU) in a phase III trial Meeting Abstract

sustainable development goals

authors

publication date

  • May 20, 2010

webpage

published in

volume

  • 28

issue

  • 15